Retrospective Multicenter Study on Outcome Measurement for Dyskinesia Improvement in Parkinson's Disease Patients with Pallidal and Subthalamic Nucleus Deep Brain Stimulation.
Parkinson’s disease
Unified Dyskinesia Rating Scale
deep brain stimulation
levodopa equivalent daily dose
levodopa-induced dyskinesia
Journal
Brain sciences
ISSN: 2076-3425
Titre abrégé: Brain Sci
Pays: Switzerland
ID NLM: 101598646
Informations de publication
Date de publication:
09 Aug 2022
09 Aug 2022
Historique:
received:
13
06
2022
revised:
02
08
2022
accepted:
06
08
2022
entrez:
26
8
2022
pubmed:
27
8
2022
medline:
27
8
2022
Statut:
epublish
Résumé
Deep brain stimulation (DBS) is an effective treatment for dyskinesia in patients with Parkinson’s disease (PD), among which the therapeutic targets commonly used include the subthalamic nucleus (STN) and the globus pallidus internus (GPi). Levodopa-induced dyskinesia (LID) is one of the common motor complications arising in PD patients on chronic treatment with levodopa. In this article, we retrospectively evaluated the outcomes of LID with the Unified Dyskinesia Rating Scale (UDysRS) in patients who underwent DBS in multiple centers with a GPi or an STN target. Meanwhile, the Med off MDS-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS-Ⅲ) and the levodopa equivalent daily dose (LEDD) were also observed as secondary indicators. PD patients with a GPi target showed a more significant improvement in the UDysRS compared with an STN target (92.9 ± 16.7% vs. 66.0 ± 33.6%, p < 0.0001). Both the GPi and the STN showed similar improvement in Med off UPDRS-III scores (49.8 ± 22.6% vs. 52.3 ± 29.5%, p = 0.5458). However, the LEDD was obviously reduced with the STN target compared with the GPi target (44.6 ± 28.1% vs. 12.2 ± 45.8%, p = 0.006).
Identifiants
pubmed: 36009117
pii: brainsci12081054
doi: 10.3390/brainsci12081054
pmc: PMC9405623
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support
ID : XMLX201833
Organisme : National Natural Science Foundation of China
ID : 81971070
Organisme : Key Research and Development Program of Ningxia
ID : 2018BFG02007
Organisme : Joint Funds for the Innovation of Science and Technology, Fujian Province
ID : 2017Y9010
Références
Front Neural Circuits. 2017 Jun 30;11:48
pubmed: 28713248
Parkinsonism Relat Disord. 2015 Nov;21(11):1349-54
pubmed: 26439944
J Neurol. 2008 Aug;255 Suppl 4:32-41
pubmed: 18821084
Lancet Neurol. 2020 Jun;19(6):491-501
pubmed: 32470421
Pract Neurol. 2015 Feb;15(1):14-25
pubmed: 25253895
N Engl J Med. 2010 Jun 3;362(22):2077-91
pubmed: 20519680
Mov Disord. 2008 Dec 15;23(16):2398-403
pubmed: 19025759
Mov Disord. 2001 May;16(3):448-58
pubmed: 11391738
Elife. 2018 Mar 23;7:
pubmed: 29570050
Neurology. 2012 Jul 3;79(1):55-65
pubmed: 22722632
Ann Clin Transl Neurol. 2020 Jan;7(1):59-68
pubmed: 31813194
Curr Neurol Neurosci Rep. 2007 Jul;7(4):302-10
pubmed: 17618536
Eur Neurol. 2017;77(5-6):281-287
pubmed: 28391276
Ann Neurol. 2018 Dec;84(6):797-811
pubmed: 30357892
Mov Disord. 2019 Jun;34(6):816-819
pubmed: 30983023
Cell Mol Life Sci. 2021 Dec 22;79(1):31
pubmed: 34936033
Commun Biol. 2021 Sep 22;4(1):1071
pubmed: 34552196
Dev Dyn. 2011 Jun;240(6):1567-77
pubmed: 21455927
JAMA Neurol. 2021 Oct 1;78(10):1212-1219
pubmed: 34491267
JAMA. 2020 Feb 11;323(6):548-560
pubmed: 32044947
J Neural Transm (Vienna). 2020 Oct;127(10):1435-1439
pubmed: 32851476
Front Neurol. 2021 Apr 12;12:595741
pubmed: 33912121
J Neurophysiol. 2016 Jan 1;115(1):19-38
pubmed: 26510756
Front Hum Neurosci. 2015 Oct 19;9:586
pubmed: 26539102
J Cell Sci. 2010 Jun 1;123(Pt 11):1922-30
pubmed: 20460439
J Neurol. 2009 Oct;256(10):1736-41
pubmed: 19536584
World Neurosurg. 2015 Nov;84(5):1294-8
pubmed: 26072454
Stereotact Funct Neurosurg. 2006;84(4):176-9
pubmed: 16905880
Neurosurg Focus. 2004 Jul 15;17(1):E3
pubmed: 15264772
Arch Neurol. 2005 Apr;62(4):554-60
pubmed: 15824252
Neurology. 1998 Mar;50(3 Suppl 3):S1-57
pubmed: 9524552